Onco-Innovations Ltd. is a Canadian biotech company, which engages in cancer research and treatment, specializing in oncology. The company is headquartered in Calgary, Alberta. The company went IPO on 2024-11-27. The firm holds an exclusive worldwide license to patented technology that targets solid tumors. The firm is engaged in developing and commercializing treatments for various types of cancer. Its solution focuses on targeting cancer cells, effectively eliminating them and preventing their regrowth. Its licensed technology focuses on Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors. Its SynoGraph platform merges genomic, proteomic, and multimodal datasets to uncover deep insights into disease mechanisms, potentially enabling more personalized and effective treatment strategies.
Follow-Up Questions
Onco-Innovations Ltd のCEOは誰ですか？
Mr. Thomas Oshaughnessy は Onco-Innovations Ltd の Chief Executive Officer で、2024 から在籍しています。
ONNVF の株価パフォーマンスは？
ONNVF の現在の価格は $1.1 で、最終取引日から 0% decreased 変動しました。
Onco-Innovations Ltd の主な事業テーマや業界は？
Onco-Innovations Ltd は Biotechnology 業界、セクターは Health Care に属しています。
